Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 33, 2014, Pages

  Yan, Dan ^a   Lee, Sujin ^b,c   Thakkar, Vidhi D ^a   Luo, Ming ^d   Moore, Martin L ^b,c   Plemper, Richard Karl ^a,b  

^a GEORGIA STATE UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Antiviral drugs; Drug resistance

Indexed keywords

1 CYCLOPROPYL 1,3 DIHYDRO 3 [[1 (4 HYDROXYBUTYL) 1H BENZIMIDAZOL 2 YL]METHYL] 2H IMIDAZO[4,5 C]PYRIDIN 2 ONE; ANTIVIRUS AGENT; COMPLEMENTARY DNA; ENFUVIRTIDE; GPAR 3710; JMN 3 003; RESPIRATORY SYNCYTIAL PNEUMOVIRUS FUSION PROTEIN; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN;

ANIMAL EXPERIMENT; ANTIVIRAL RESISTANCE; ARTICLE; CROSS RESISTANCE; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIROGENESIS; VIRUS ENTRY; VIRUS REPLICATION;

ANTIVIRAL DRUGS; DRUG RESISTANCE;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CRICETINAE; DRUG RESISTANCE, VIRAL; MEMBRANE FUSION; MICE, INBRED BALB C; MUTATION; RESPIRATORY SYNCYTIAL VIRUSES; SMALL MOLECULE LIBRARIES; VIRAL PROTEINS;

EID: 84906328204     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1405198111     Document Type: Article

References (61)

1. Thompson WW, et al. (2003) Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289(2):179-186. (Pubitemid 36068705)
2. Elliot AJ, Fleming DM (2008) Influenza and respiratory syncytial virus in the elderly. Expert Rev Vaccines 7(2):249-258. (Pubitemid 351357959)
3. Ebbert JO, Limper AH (2005) Respiratory syncytial virus pneumonitis in immunocompromised adults: Clinical features and outcome. Respiration 72(3):263-269. (Pubitemid 40981085)
4. Collins PL, Crowe JE, Jr (2007) Respiratory syncytial virus and metapneumoviruses. Fields Virology, eds Knipe DM, Howley PM (Lippincott Williams & Wilkins, Philadelphia), 5th Ed, Vol 2, pp 1601-1645.
5. Mahadevia PJ, Masaquel AS, Polak MJ, Weiner LB (2012) Cost utility of palivizumab prophylaxis among pre-term infants in the United States: A national policy perspective. J Med Econ 15(5):987-996.
6. Aherne W, Bird T, Court SD, Gardner PS, McQuillin J (1970) Pathological changes in virus infections of the lower respiratory tract in children. J Clin Pathol 23(1):7-18.
7. Lugo RA, Nahata MC (1993) Pathogenesis and treatment of bronchiolitis. Clin Pharm 12(2):95-116. (Pubitemid 23035002)
8. Anderson LJ, Parker RA, Strikas RL (1990) Association between respiratory syncytial virus outbreaks and lower respiratory tract deaths of infants and young children. J Infect Dis 161(4):640-646. (Pubitemid 20120219)
9. Hall CB, et al. (1993) American Academy of Pediatrics Committee on Infectious Diseases: Use of ribavirin in the treatment of respiratory syncytial virus infection. Pediatrics 92(3):501-504. (Pubitemid 23264664)
10. Broor S, et al. (2007) A prospective three-year cohort study of the epidemiology and virology of acute respiratory infections of children in rural India. PLoS ONE 2(6):e491.
11. Mahadevia PJ, Makari D, Masaquel A (2012) Methodological concerns regarding cost-effectiveness analysis of palivizumab in Florida Medicaid. Arch Pediatr Adolesc Med 166(10):968-969, author reply 969-970.
12. Kamal-Bahl S, Doshi J, Campbell J (2002) Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: A systematic review. Arch Pediatr Adolesc Med 156(10):1034-1041. (Pubitemid 36343482)
13. Hampp C, Kauf TL, Saidi AS, Winterstein AG (2011) Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolesc Med 165(6):498-505.
14. de Vries RD, Mesman AW, Geijtenbeek TB, Duprex WP, de Swart RL (2012) The pathogenesis of measles. Curr Opin Virol 2(3):248-255.
15. Griffin DE (2010) Measles virus-induced suppression of immune responses. Immunol Rev 236:176-189.
16. DeVincenzo JP, El Saleeby CM, Bush AJ (2005) Respiratory syncytial virus load predicts disease severity in previously healthy infants. J Infect Dis 191(11):1861-1868. (Pubitemid 40705393)
17. El Saleeby CM, Bush AJ, Harrison LM, Aitken JA, Devincenzo JP (2011) Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J Infect Dis 204(7):996-1002.
18. Teng MN, Whitehead SS, Collins PL (2001) Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology 289(2):283-296. (Pubitemid 33141008)
19. Techaarpornkul S, Barretto N, Peeples ME (2001) Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. J Virol 75(15):6825-6834. (Pubitemid 32641568)
20. Techaarpornkul S, Collins PL, Peeples ME (2002) Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus. Virology 294(2):296-304. (Pubitemid 34920528)
21. Roymans D, et al. (2010) Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proc Natl Acad Sci USA 107(1):308-313.
22. Douglas JL, et al. (2005) Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. Antimicrob Agents Chemother 49(6):2460-2466. (Pubitemid 40734480)
23. Cianci C, et al. (2004) Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob Agents Chemother 48(2):413-422. (Pubitemid 38141696)
24. Morton CJ, et al. (2003) Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: Homology model of the F protein and a syncytium formation assay. Virology 311(2):275-288. (Pubitemid 36808771)
25. Berkhout B, Eggink D, Sanders RW (2012) Is there a future for antiviral fusion inhibitors? Curr Opin Virol 2(1):50-59.
26. McLellan JS, et al. (2013) Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342(6158):592-598.
27. McLellan JS, Yang Y, Graham BS, Kwong PD (2011) Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol 85(15):7788-7796.
28. Swanson KA, et al. (2011) Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci USA 108(23):9619-9624.
29. Plemper RK (2011) Cell entry of enveloped viruses. Curr Opin Virol 1(2):92-100.
30. Cianci C, et al. (2004) Targeting a binding pocket within the trimer-of-hairpins: Small-molecule inhibition of viral fusion. Proc Natl Acad Sci USA 101(42):15046-15051. (Pubitemid 39391716)
31. Roymans D, Koul A (2011) Treatment of respiratory syncytial virus infection: Past, present and future. Human Respiratory Syncytial Virus Infection, ed Resch B (InTech, Rijeka, Croatia), pp 197-215.
32. Hotard AL, et al. (2012) A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. Virology 434(1):129-136.
33. Yan D, et al. (2013) Dual myxovirus screen identifies a small-molecule agonist of the host antiviral response. J Virol 87(20):11076-11087.
34. Krumm SA, et al. (2011) Potent host-directed small-molecule inhibitors of myxovirus RNA-dependent RNA-polymerases. PLoS ONE 6(5):e20069.
35. Brindley MA, Takeda M, Plattet P, Plemper RK (2012) Triggering the measles virus membrane fusion machinery. Proc Natl Acad Sci USA 109(44):E3018-E3027.
36. Dochow M, Krumm SA, Crowe JE, Jr, Moore ML, Plemper RK (2012) Independent structural domains in paramyxovirus polymerase protein. J Biol Chem 287(9):6878-6891.
37. Kondo N, Miyauchi K, Matsuda Z (2011) Monitoring viral-mediated membrane fusion using fluorescent reporter methods. Curr Protoc Cell Biol Chapter 26:Unit 26.29.
38. Moore ML, et al. (2009) A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J Virol 83(9):4185-4194.
39. Côté M, Zheng YM, Liu SL (2009) Receptor binding and low pH coactivate oncogenic retrovirus envelope-mediated fusion. J Virol 83(22):11447-11455.
40. Stokes KL, et al. (2011) Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J Virol 85(12):5782-5793.
41. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS (2007) The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 20(1):108-119. (Pubitemid 44967956)
42. Lee S, et al. (2012) Vaccine-elicited CD8+ T cells protect against respiratory syncytial virus strain A2-line19F-induced pathogenesis in BALB/c mice. J Virol 86(23):13016-13024.
43. Hancock GE, et al. (1996) Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J Virol 70(11):7783-7791. (Pubitemid 26339084)
44. Murphy BR, Sotnikov AV, Lawrence LA, Banks SM, Prince GA (1990) Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 8(5):497-502. (Pubitemid 20332861)
45. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE (1969) An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 89(4):405-421.
46. Kim HW, et al. (1969) Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89(4):422-434.
47. Collins PL, Melero JA (2011) Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years. Virus Res 162(1-2):80-99.
48. Lamb RA, Parks GD (2007) Paramyxoviridae: The viruses and their replication. Fields Virology, eds Knipe DM, Howley PM (Lippincott Williams & Wilkins, Philadelphia), 5th Ed, Vol 1, pp 1449-1496.
49. Lee JK, Prussia A, Snyder JP, Plemper RK (2007) Reversible inhibition of the fusion activity of measles virus F protein by an engineered intersubunit disulfide bridge. J Virol 81(16):8821-8826. (Pubitemid 47242855)
50. Yin HS, Wen X, Paterson RG, Lamb RA, Jardetzky TS (2006) Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature 439(7072):38-44. (Pubitemid 43053622)
51. Doyle J, et al. (2006) Two domains that control prefusion stability and transport competence of the measles virus fusion protein. J Virol 80(3):1524-1536. (Pubitemid 43134108)
52. Eggink D, et al. (2009) Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. J Biol Chem 284(39):26941-26950.
53. Baldwin CE, et al. (2004) Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol 78(22):12428-12437. (Pubitemid 39458761)
54. Reeves JD, et al. (2005) Enfuvirtide resistance mutations: Impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol 79(8):4991-4999. (Pubitemid 40464249)
55. Lukacs NW, et al. (2006) Differential immune responses and pulmonary pathophysiology are induced by two different strains of respiratory syncytial virus. Am J Pathol 169(3):977-986. (Pubitemid 44411960)
56. Radecke F, et al. (1995) Rescue of measles viruses from cloned DNA. EMBO J 14(23):5773-5784.
57. Moore TW, et al. (2013) Synthesis and metabolic studies of host directed inhibitors for anti viral therapy. ACS Med Chem Lett 4(8):762-767.
58. Boutros M, Brás LP, Huber W (2006) Analysis of cell-based RNAi screens. Genome Biol 7(7):R66.
59. Pelz O, Gilsdorf M, Boutros M (2010) web cellHTS2: A web-application for the analysis of high-throughput screening data. BMC Bioinformatics 11:185.
60. Brindley MA, et al. (2013) A stabilized headless measles virus attachment protein stalk efficiently triggers membrane fusion. J Virol 87(21):11693-11703.
61. Plemper RK, Compans RW (2003) Mutations in the putative HR-C region of the measles virus F2 glycoprotein modulate syncytium formation. J Virol 77(7):4181-4190. (Pubitemid 36350957)